IL6 and cancer: These consist of direct STAT3 inhibitors (peptides, small molecules, oligonucleotides), indirect inhibitors (JAKs, IL-6, EGFR) or those that can be combined with immunotherapy (e.g. immune checkpoint inhibitors, CAR-T cell therapy, dendritic cell based cancer vaccine and immunostimulatory Toll Ligand Receptor (TLR) agonists) (71).